vs

Side-by-side financial comparison of BXP, Inc. (BXP) and Royalty Pharma plc (RPRX). Click either name above to swap in a different company.

BXP, Inc. is the larger business by last-quarter revenue ($872.1M vs $622.0M, roughly 1.4× Royalty Pharma plc). Royalty Pharma plc runs the higher net margin — 34.4% vs 15.3%, a 19.2% gap on every dollar of revenue. On growth, Royalty Pharma plc posted the faster year-over-year revenue change (4.8% vs 0.8%). Over the past eight quarters, Royalty Pharma plc's revenue compounded faster (4.6% CAGR vs 1.3%).

BXP Inc., operating as Boston Properties, is a leading U.S. real estate investment trust focused on owning, managing and developing high-quality Class A commercial office properties across major U.S. metro markets, serving diverse corporate, tech and professional service tenants.

Acceleron Pharma, Inc. is an American clinical stage biopharmaceutical company based in Cambridge, Massachusetts with a broad focus on developing medicines that regulate the transforming growth factor beta (TGF-β) superfamily of proteins, which play fundamental roles in the growth and repair of cells and tissues such as red blood cells, muscle, bone, and blood vessels.

BXP vs RPRX — Head-to-Head

Bigger by revenue
BXP
BXP
1.4× larger
BXP
$872.1M
$622.0M
RPRX
Growing faster (revenue YoY)
RPRX
RPRX
+4.0% gap
RPRX
4.8%
0.8%
BXP
Higher net margin
RPRX
RPRX
19.2% more per $
RPRX
34.4%
15.3%
BXP
Faster 2-yr revenue CAGR
RPRX
RPRX
Annualised
RPRX
4.6%
1.3%
BXP

Income Statement — Q1 FY2026 vs Q4 FY2025

Metric
BXP
BXP
RPRX
RPRX
Revenue
$872.1M
$622.0M
Net Profit
$133.0M
$214.2M
Gross Margin
Operating Margin
62.4%
Net Margin
15.3%
34.4%
Revenue YoY
0.8%
4.8%
Net Profit YoY
53.0%
2.9%
EPS (diluted)
$1.69
$0.49

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
BXP
BXP
RPRX
RPRX
Q1 26
$872.1M
Q4 25
$877.1M
$622.0M
Q3 25
$871.5M
$609.3M
Q2 25
$868.5M
$578.7M
Q1 25
$865.2M
$568.2M
Q4 24
$858.6M
$593.6M
Q3 24
$859.2M
$564.7M
Q2 24
$850.5M
$537.3M
Net Profit
BXP
BXP
RPRX
RPRX
Q1 26
$133.0M
Q4 25
$248.4M
$214.2M
Q3 25
$-121.7M
$288.2M
Q2 25
$89.0M
$30.2M
Q1 25
$61.2M
$238.3M
Q4 24
$-228.9M
$208.2M
Q3 24
$83.6M
$544.0M
Q2 24
$79.6M
$102.0M
Gross Margin
BXP
BXP
RPRX
RPRX
Q1 26
Q4 25
58.8%
Q3 25
59.3%
Q2 25
59.2%
Q1 25
59.2%
Q4 24
59.7%
Q3 24
59.5%
Q2 24
59.8%
Operating Margin
BXP
BXP
RPRX
RPRX
Q1 26
Q4 25
62.4%
Q3 25
70.1%
Q2 25
36.3%
Q1 25
94.0%
Q4 24
60.9%
Q3 24
Q2 24
50.2%
Net Margin
BXP
BXP
RPRX
RPRX
Q1 26
15.3%
Q4 25
28.3%
34.4%
Q3 25
-14.0%
47.3%
Q2 25
10.2%
5.2%
Q1 25
7.1%
41.9%
Q4 24
-26.7%
35.1%
Q3 24
9.7%
96.3%
Q2 24
9.4%
19.0%
EPS (diluted)
BXP
BXP
RPRX
RPRX
Q1 26
$1.69
Q4 25
$1.56
$0.49
Q3 25
$-0.77
$0.67
Q2 25
$0.56
$0.07
Q1 25
$0.39
$0.55
Q4 24
$-1.46
$0.46
Q3 24
$0.53
$1.21
Q2 24
$0.51
$0.23

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
BXP
BXP
RPRX
RPRX
Cash + ST InvestmentsLiquidity on hand
$512.8M
$618.7M
Total DebtLower is stronger
$9.0B
Stockholders' EquityBook value
$7.7B
$9.7B
Total Assets
$25.1B
$19.6B
Debt / EquityLower = less leverage
0.92×

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
BXP
BXP
RPRX
RPRX
Q1 26
$512.8M
Q4 25
$1.5B
$618.7M
Q3 25
$861.1M
$938.9M
Q2 25
$447.0M
$631.9M
Q1 25
$398.1M
$1.1B
Q4 24
$1.3B
$929.0M
Q3 24
$1.4B
$950.1M
Q2 24
$685.4M
$1.8B
Total Debt
BXP
BXP
RPRX
RPRX
Q1 26
Q4 25
$9.0B
Q3 25
$8.9B
Q2 25
$8.0B
Q1 25
$7.6B
Q4 24
$7.6B
Q3 24
$7.6B
Q2 24
$7.6B
Stockholders' Equity
BXP
BXP
RPRX
RPRX
Q1 26
$7.7B
Q4 25
$5.1B
$9.7B
Q3 25
$5.0B
$9.6B
Q2 25
$5.3B
$9.5B
Q1 25
$5.3B
$9.8B
Q4 24
$5.4B
$10.3B
Q3 24
$5.8B
$10.3B
Q2 24
$5.8B
$9.8B
Total Assets
BXP
BXP
RPRX
RPRX
Q1 26
$25.1B
Q4 25
$26.2B
$19.6B
Q3 25
$26.0B
$19.3B
Q2 25
$25.6B
$18.3B
Q1 25
$25.4B
$17.6B
Q4 24
$26.1B
$18.2B
Q3 24
$26.4B
$18.0B
Q2 24
$25.5B
$17.7B
Debt / Equity
BXP
BXP
RPRX
RPRX
Q1 26
Q4 25
0.92×
Q3 25
0.93×
Q2 25
0.84×
Q1 25
0.78×
Q4 24
0.74×
Q3 24
0.74×
Q2 24
0.78×

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
BXP
BXP
RPRX
RPRX
Operating Cash FlowLast quarter
$827.1M
Free Cash FlowOCF − Capex
FCF MarginFCF / Revenue
Capex IntensityCapex / Revenue
1.5%
Cash ConversionOCF / Net Profit
3.86×
TTM Free Cash FlowTrailing 4 quarters

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
BXP
BXP
RPRX
RPRX
Q1 26
Q4 25
$407.8M
$827.1M
Q3 25
$274.2M
$702.6M
Q2 25
$353.1M
$364.0M
Q1 25
$210.0M
$596.1M
Q4 24
$383.7M
$742.5M
Q3 24
$286.1M
$703.6M
Q2 24
$367.1M
$658.2M
Free Cash Flow
BXP
BXP
RPRX
RPRX
Q1 26
Q4 25
$362.7M
Q3 25
$231.6M
Q2 25
$281.5M
Q1 25
$152.6M
Q4 24
$312.5M
Q3 24
$234.5M
Q2 24
$332.4M
FCF Margin
BXP
BXP
RPRX
RPRX
Q1 26
Q4 25
41.4%
Q3 25
26.6%
Q2 25
32.4%
Q1 25
17.6%
Q4 24
36.4%
Q3 24
27.3%
Q2 24
39.1%
Capex Intensity
BXP
BXP
RPRX
RPRX
Q1 26
1.5%
Q4 25
5.1%
Q3 25
4.9%
Q2 25
8.2%
Q1 25
6.6%
Q4 24
8.3%
Q3 24
6.0%
Q2 24
4.1%
Cash Conversion
BXP
BXP
RPRX
RPRX
Q1 26
Q4 25
1.64×
3.86×
Q3 25
2.44×
Q2 25
3.97×
12.06×
Q1 25
3.43×
2.50×
Q4 24
3.57×
Q3 24
3.42×
1.29×
Q2 24
4.61×
6.45×

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Revenue Breakdown by Segment

BXP
BXP

Lease$818.2M94%
Parking and other$30.8M4%
Development and management services$9.2M1%

RPRX
RPRX

Financial Royalty Assets$592.4M95%
Royalty Income Other$29.6M5%

Related Comparisons